Xencor (XNCR) Equity Income (2020 - 2026)
Xencor (XNCR) reported Equity Income of -$51.9 million for Q1 2026, down 5618.49% year-over-year from $941000.0 in Q1 2025, and down 201.02% quarter-over-quarter from $51.4 million in Q4 2025.
Xencor (XNCR) Equity Income (2020 - 2026) Analysis & Trends
Xencor (XNCR) has 7 years of Equity Income data on file, last reported at -$51.9 million in Q1 2026.
- Equity Income for Q1 2026 came in at -$51.9 million, down 5618.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $48.6 million (up 248.28% YoY), and the FY2025 annual result was $101.5 million, up 423.07% from the prior year.
- Equity Income slipped to -$51.9 million in Q1 2026 per XNCR's latest filing, from $51.4 million in the prior quarter.
- Over five years, Equity Income peaked at $51.4 million in Q4 2025 and troughed at -$51.9 million in Q1 2026.
- A 5-year average of $2.4 million and a median of $941000.0 in 2025 frame the typical range for Equity Income.
- On a YoY basis, Equity Income climbed as much as 488.78% in 2022 and fell as far as 340100.0% in 2022.
- A 5-year view of Equity Income shows it stood at $28.1 million in 2022, then slumped by 52.89% to $13.2 million in 2023, then sank by 333.98% to -$31.0 million in 2024, then soared by 265.96% to $51.4 million in 2025, then plunged by 201.02% to -$51.9 million in 2026.
- Business Quant data shows XNCR's Equity Income at -$51.9 million in Q1 2026, $51.4 million in Q4 2025, and $44.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | -51.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51.93 Mn |
| Dec 31, 2025 | 51.41 Mn |
| Sep 30, 2025 | 44.20 Mn |
| Jun 30, 2025 | 4.97 Mn |
| Mar 31, 2025 | 941,000.00 |
| Dec 31, 2024 | -30.97 Mn |
| Sep 30, 2024 | 9.25 Mn |
| Jun 30, 2024 | -12.03 Mn |
| Mar 31, 2024 | 2.33 Mn |
| Dec 31, 2023 | 13.24 Mn |
| Sep 30, 2023 | -11.02 Mn |
| Jun 30, 2023 | 300,000.00 |
| Mar 31, 2023 | -2.90 Mn |
| Dec 31, 2022 | 28.10 Mn |
| Sep 30, 2022 | 5.30 Mn |
| Jun 30, 2022 | -6.55 Mn |
| Mar 31, 2022 | -3.40 Mn |
| Dec 31, 2021 | 20.99 Mn |
| Sep 30, 2021 | 900,000.00 |
| Jun 30, 2021 | 18.30 Mn |